Core Viewpoint - The stock of Insilico Medicine (03696) surged over 11% on its second day of trading, reaching HKD 33.62, nearly a 40% increase from its IPO price of HKD 24.05 [1] Company Summary - Insilico Medicine, established in 2014, is a leading company in AI-driven drug discovery and development in China [1] - By December 10, 2025, the company is expected to generate over 20 clinical or IND application-stage assets through its proprietary generative AI platform, Pharma.AI [1] - Three of these assets have been licensed to international pharmaceutical companies, with a total contract value of up to USD 2.1 billion, alongside one Phase II asset currently in self-development [1] Industry Summary - According to Frost & Sullivan, the AI drug discovery and development (AIDD) market is projected to grow from USD 11.9 billion in 2023 to USD 74.6 billion by 2032, with a compound annual growth rate (CAGR) of 22.6% [1]

Group 1 - The core viewpoint of the article highlights the significant stock performance of InSilico Medicine (03696) on its second day of trading, with a rise of over 11%, reaching HKD 33.62, which is nearly a 40% increase from the IPO price of HKD 24.05 [1] - As of the report, the stock is up 11.14%, priced at HKD 33.32, with a trading volume of HKD 83.89 million and a total market capitalization exceeding HKD 18 billion [1] - InSilico Medicine, established in 2014, is recognized as a leading company in AI-driven drug discovery and development in China [1] Group 2 - By December 10, 2025, the company is expected to generate over 20 clinical or IND application stage assets through its proprietary generative AI platform, Pharma.AI, with three assets already licensed to international pharmaceutical companies, totaling a contract value of up to USD 2.1 billion [1] - The company also has one asset in Phase II of its independent development, which is considered to be at a leading stage in the industry [1] - According to Frost & Sullivan, the AI drug discovery and development (AIDD) market is projected to grow from USD 11.9 billion in 2023 to USD 74.6 billion by 2032, with a compound annual growth rate (CAGR) of 22.6% [1]